(2)
INDIANAPOLIS (dpa-AFX) - Today s Daily Dose brings you news about the effectiveness of Lilly s Bamlanivimab in reducing the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, executive changes at BiondVax Pharma, regulatory update on Genetic Technologies COVID-19 PRS Test, Adamis SYMJEPI products being made available in the Walgreens Prescription Savings Club, Fluidigm s Advanta Dx SARS-CoV-2 RT-PCR Assay receiving the CE-IVD mark.
Read on.
1. Adamis to Offer SYMJEPI in Walgreens Prescription Savings Club
Adamis Pharmaceuticals Corporation (ADMP) surged more than 90% in after-hours Thursday, on news of its SYMJEPI products now being available to members of the Walgreens Prescription Savings Club program.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion .
Genetic Technologies LtdJanuary 21, 2021 GMT
MELBOURNE, Australia, Jan. 21, 2021 (GLOBE NEWSWIRE) Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company’s offering to include Germline Testing division.
Key Highlights
Total COVID-19 positive patient data analyzed exceeds 5,500 following inclusion of further 4,000 patients’ data
Mid-Morning Market Update: Markets Mixed; Union Pacific Profit Beats Views benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
60 Stocks Moving In Thursday s Mid-Day Session Benzinga 12/10/2020
Gainers
Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its Chinese partner, EOC Pharma will commence a new Phase 2 clinical trial of Immutep s eftilagimod alpha in up to 152 metastatic breast cancer patients in China. Immutep said the study follows encouraging data reported by it in its APIAC Phase 2b study announced at the end of March and presented at the SABCS.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) shares surged 67.4% to $95.60. Greenwich LifeSciences shares jumped 998% on Wednesday after the company shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented Wednesday at the 2020 San Antonio Breast Cancer Symposium.